Rome, May 2 – The pharmaceutical industry is increasingly interested in the search for drugs to treat diseases that primarily affect women: there are currently about 600 studies in the world for the development of drugs against diseases of the female sex, which shows “The growing concern of the pharmaceutical industry towards gender differences”.
Theor said Lucia Aloti (in the picture)Shareholder and Director of Menarini and Vice President of Farmindustria, speaking April 28 at a webinar MoltoDonna – perversions of female sex “organized by the newspaper Prophet.
ELLIOTI – SUMMARY THE AGENCY InTerris Highlight the number of women participating in clinical studies in the last 30 years ‘It has increased a lot’ after stage, “Until the 1990s, when they were largely excluded by the misconception that the only difference between a man and a woman was in the reproductive part”. Today, however, . “We are aware that medicines have different effects and efficacy when taken by men or women,” for this reason. “For some diseases, we have drugs that are only approved for women, because they have not been shown to be effective in men.”.
So the Vice President of Farmindustria warned that there is a very clear view between male and female diseases. “The taboo or the misconception that breast cancer is an exclusively female disease must be eliminated, because it is not.”. This is why studies of 600 drugs against diseases that mostly affect women also include men: “In fact, we are talking about female-dominated diseases, not exclusively. So it is also important to study the effects of these drugs on men”He outlined Allotti, explaining that the real goal is personalized medicine and the creation of medicines that take into account the specific circumstances of each individual patient and not just the fact that he or she is male or female. “Knowing the biological mechanisms allows us to understand that disease no longer exists as a single form” The industrial manager said about her. “Each drug interacts differently with the body, depending on the person, and gives different answers.”
Then Eliotte concluded by noting that We have entered an exceptional era of medical advances. If we can ensure the growth of openness and collaboration between science, industry, academia, and institutions in our country as well, we will not only offer new treatments, but also provide many skills and opportunities for women and for the country.”